Previous 10 | Next 10 |
UroGen Pharma press release (NASDAQ:URGN): Q1 GAAP EPS of -$1.25 beats by $0.09. Revenue of $13.56M (+81.0% Y/Y) misses by $1.62M. For further details see: UroGen Pharma GAAP EPS of -$1.25 beats by $0.09, revenue of $13.56M misses by $1.62M
Jelmyto® net product revenue increased 81% over Q1 2021 to $13.6 million Enrollment of UGN-102 Phase 3 single-arm, ENVISION pivotal trial is ongoing; completion of enrollment expected by end of 2022 Initiated novel, multi-arm Phase 1 clinical trial of UGN-301 in...
U.S. Food and Drug Administration (FDA) approval received for VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for treatment of H. pylori infection in adults Up to $260 million revenue...
Conference Call and Webcast Scheduled for Tuesday, May 10, 2022 at 10:00 AM ET UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will repo...
UroGen Pharma (NASDAQ:URGN), the developer of RTGel drug delivery platform, is trading higher on Wednesday after Berenberg Capital Markets launched its coverage with a Buy recommendation noting its prospects in bladder cancers. The analyst Anita Dushyanth sees $2 billion market opportunity fo...
Gainers: Burning Rock Biotech Limited (BNR) +5%. Hemisphere Media Group (HMTV) +4%. Neuronetics (STIM) +4%. AvePoint (AVPT) +3%. Jounce Therapeutics (JNCE) +3%. Losers: UroGen Pharma (URGN) -12%. Purple Innovation (PRPL) -5%. Trinity Capital (TRIN) -4%. ...
UroGen Pharma (NASDAQ:URGN) said the U.S. Food and Drug Administration (FDA) cleared its investigational new drug application to begin a phase 1 trial of UGN-301 (zalifrelimab) in patients with recurrent non-muscle invasive bladder cancer (NMIBC). The company said the multi-arm phase 1 t...
--Multi-arm Phase 1 study will evaluate the safety, tolerability and establish the recommended Phase 2 dose of monotherapy and combination therapy to treat recurrent non-muscle invasive bladder cancer (NMIBC) --Study design utilizes Master Protocol to accelerate evaluation of combin...
Phathom Pharmaceuticals (NASDAQ:PHAT) stated Tuesday that it has appointed Molly Henderson as the company's new chief financial and business officer, effective Apr. 5, 2022. Henderson has most recently served as CFO of UroGen Pharma (URGN), and previously at Advaxis (OTC:ADXS)....
FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson t...
News, Short Squeeze, Breakout and More Instantly...
2024-06-25 07:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the pricing of an underwritten public offering of 5,000,000 ordinary shares at a price to the public of $17.50 per ord...
PRINCETON, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has commenced an underwritten public offering, subject to m...